Gå til innholdet
Global sound
BioCentury This Week

BioCentury This Week

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

· 35 min · Sesong 7 Episode 351

Episodebeskrivelse

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does for the Foster City, Calif.-based biotech’s pipeline. The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which foc...

Live, siste time: 6 371 låter på 2 740 stasjoner i 120 land

Oppdag verden gjennom radioen

Flere måter å oppdage på (7)

Hørt noe fint? Lagre det, eller åpne det rett i Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
93.7 The Mountain KDRK FMFortsett å lytte